标题
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
作者
关键词
-
出版物
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-09-09
DOI
10.3389/fcell.2020.564601
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- TRIP13 regulates DNA repair pathway choice through REV7 conformational change
- (2020) Connor S. Clairmont et al. NATURE CELL BIOLOGY
- A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study
- (2020) P A Baxter et al. NEURO-ONCOLOGY
- The kinase polypharmacology landscape of clinical PARP inhibitors
- (2020) Albert A. Antolin et al. Scientific Reports
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
- (2020) Marco Gatti et al. Cell Reports
- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
- (2019) R. Tuli et al. EBioMedicine
- NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
- (2019) Chunjing Bian et al. Nature Communications
- The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis
- (2019) Mok Oh et al. PROSTATE
- The ATP-bound conformation of the Mre11–Rad50 complex is essential for Tel1/ATM activation
- (2019) Corinne Cassani et al. NUCLEIC ACIDS RESEARCH
- PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
- (2019) Xuan Jiang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers
- (2019) Bernardo P. de Almeida et al. BMC CANCER
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
- (2019) Isabella Faraoni et al. BIOCHEMICAL PHARMACOLOGY
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition
- (2019) Janet R Vos et al. JNCI-Journal of the National Cancer Institute
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
- (2019) Daniela Criscuolo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21
- (2019) Dae-Seok Kim et al. MOLECULAR CELL
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- A systematic review of the international prevalence of BRCA mutation in breast cancer
- (2019) Nigel Armstrong et al. Clinical Epidemiology
- DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
- (2019) Thiago Vidotto et al. Journal for ImmunoTherapy of Cancer
- Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications
- (2019) Xianwen Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
- (2019) Maximilian Brunner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group
- (2019) Hualei Bu et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
- (2019) Michael Friedlander et al. LANCET ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- 846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
- (2019) W Abida et al. ANNALS OF ONCOLOGY
- Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
- (2019) Jing Luo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage
- (2019) Emma Bolderson et al. Nature Communications
- Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
- (2019) Jerry H. Houl et al. Nature Communications
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
- (2018) Rajat Gupta et al. CELL
- BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
- (2018) Erica L. Gornstein et al. Clinical Breast Cancer
- Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
- (2018) James H Laird et al. CLINICAL CANCER RESEARCH
- An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
- (2018) Nicholas Pulliam et al. CLINICAL CANCER RESEARCH
- A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
- (2018) Shoko Vos et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
- (2018) Tuo Li et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- (2018) Hana Hanzlikova et al. MOLECULAR CELL
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- Assembling a protective shield
- (2018) Roger A Greenberg NATURE CELL BIOLOGY
- Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
- (2018) Jone Michelena et al. Nature Communications
- The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
- (2018) Elizaveta Alemasova et al. Oncotarget
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
- (2018) Hongwei Liao et al. EMBO REPORTS
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- Superfast DNA replication causes damage in cancer cells
- (2018) Annabel Quinet et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
- (2018) Dan Le et al. Expert Review of Clinical Pharmacology
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
- (2018) S.A. Hurvitz et al. EUROPEAN JOURNAL OF CANCER
- PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
- (2018) Todd A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- Epidemiology of lung cancer in China
- (2018) Maomao Cao et al. Thoracic Cancer
- Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
- (2018) Paola Francica et al. Genome Medicine
- Pattern Recognition Receptors and the Host Cell Death Molecular Machinery
- (2018) Gustavo P. Amarante-Mendes et al. Frontiers in Immunology
- BRCA Mutations and Breast Cancer Prevention
- (2018) Joanne Kotsopoulos Cancers
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
- (2017) Diana Mandelker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
- (2017) Leslie A. Parsels et al. MOLECULAR CANCER RESEARCH
- Serine ADP-Ribosylation Depends on HPF1
- (2017) Juan José Bonfiglio et al. MOLECULAR CELL
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
- (2017) Frank Lyko NATURE REVIEWS GENETICS
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1
- (2017) Lili Liu et al. NUCLEIC ACIDS RESEARCH
- EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
- (2017) H Yamaguchi et al. ONCOGENE
- Triple-negative breast cancer and the potential for targeted therapy
- (2017) Jing-Ru Jhan et al. PHARMACOGENOMICS
- Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review
- (2017) Michal Chovanec et al. Targeted Oncology
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
- (2017) Pepijn M. Schoonen et al. Nature Communications
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- PARP inhibition causes premature loss of cohesion in cancer cells
- (2017) Eva Kukolj et al. Oncotarget
- The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
- (2017) et al. Cancers
- Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study
- (2017) Alison Pearce et al. PLoS One
- Y-box-binding protein 1 as a non-canonical factor of base excision repair
- (2016) Elizaveta E. Alemasova et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
- (2016) Nidal E. Muvarak et al. CANCER CELL
- Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
- (2016) K. W. Pratz et al. CLINICAL CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Patients’ perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey
- (2016) Domenica Lorusso et al. EUROPEAN JOURNAL OF CANCER CARE
- Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
- (2016) Dong Wang et al. GYNECOLOGIC ONCOLOGY
- Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
- (2016) Pierre Chabot et al. JOURNAL OF NEURO-ONCOLOGY
- HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
- (2016) Ian Gibbs-Seymour et al. MOLECULAR CELL
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Serine is a new target residue for endogenous ADP-ribosylation on histones
- (2016) Orsolya Leidecker et al. Nature Chemical Biology
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin
- (2016) Hana Hanzlikova et al. NUCLEIC ACIDS RESEARCH
- Protein dynamics of human RPA and RAD51 on ssDNA during assembly and disassembly of the RAD51 filament
- (2016) Chu Jian Ma et al. NUCLEIC ACIDS RESEARCH
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis
- (2016) Abhishek A. Singh et al. Oncotarget
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- Sam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ation
- (2016) Xin Sun et al. PLOS BIOLOGY
- Sam68/KHDRBS1-dependent NF-κB activation confers radioprotection to the colon epithelium in γ-irradiated mice
- (2016) Kai Fu et al. eLife
- Sam68/KHDRBS1 is critical for colon tumorigenesis by regulating genotoxic stress-induced NF-κB activation
- (2016) Kai Fu et al. eLife
- Measuring quality of life after radical prostatectomy from the patient’s perspective
- (2016) Joseph L. Chin CUAJ-Canadian Urological Association Journal
- DAMPs, ageing, and cancer: The ‘DAMP Hypothesis’
- (2015) Jin Huang et al. AGEING RESEARCH REVIEWS
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- In cellulophosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA damage
- (2015) Mukesh Kumar Sharma et al. JOURNAL OF RADIATION RESEARCH
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
- (2015) Maria Teresa Esposito et al. NATURE MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulators of homologous recombination repair as novel targets for cancer treatment
- (2015) Małgorzata Krajewska et al. Frontiers in Genetics
- PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
- (2015) Jara Majuelos-Melguizo et al. Oncotarget
- The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases
- (2014) Stéphanie Solier et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- Holliday junction resolution: Regulation in space and time
- (2014) Joao Matos et al. DNA REPAIR
- Transcriptional Roles of PARP1 in Cancer
- (2014) Matthew J. Schiewer et al. MOLECULAR CANCER RESEARCH
- Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
- (2014) Julie K. Horton et al. MOLECULAR CANCER RESEARCH
- PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
- (2014) Carole Beck et al. NUCLEIC ACIDS RESEARCH
- PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
- (2014) Marie-France Langelier et al. NUCLEIC ACIDS RESEARCH
- PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
- (2014) Benu Brata Das et al. NUCLEIC ACIDS RESEARCH
- Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
- (2014) Romana Koppensteiner et al. PLoS One
- Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
- (2014) GRAZIA PALOMBA et al. Oncology Letters
- Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition
- (2014) E. Gonzalez-Billalabeitia et al. Cancer Discovery
- PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
- (2014) Y. Hu et al. Cancer Discovery
- MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability
- (2014) Young Eun Choi et al. eLife
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
- (2013) T. J. Gaymes et al. HAEMATOLOGICA
- Role of Replication Protein A in Double Holliday Junction Dissolution Mediated by the BLM-Topo IIIα-RMI1-RMI2 Protein Complex
- (2013) Xiaoyu Xue et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
- (2013) A. Min et al. MOLECULAR CANCER THERAPEUTICS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
- (2013) Y. Maede et al. MOLECULAR CANCER THERAPEUTICS
- RPA Coordinates DNA End Resection and Prevents Formation of DNA Hairpins
- (2013) Huan Chen et al. MOLECULAR CELL
- The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair
- (2013) Amanda L. Fenton et al. NUCLEIC ACIDS RESEARCH
- Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation
- (2013) WooKee Min et al. Nature Communications
- The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
- (2012) J Iqbal et al. BRITISH JOURNAL OF CANCER
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
- (2012) S. Ying et al. CANCER RESEARCH
- PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1
- (2012) Alex Pines et al. JOURNAL OF CELL BIOLOGY
- The p65 subunit of NF-κB and PARP1 assist Snail1 in activating fibronectin transcription
- (2012) Jelena Stanisavljevic et al. JOURNAL OF CELL SCIENCE
- The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
- (2012) Ammar A E Ali et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1
- (2012) M-H Lee et al. ONCOGENE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells
- (2011) Zhiyong Mao et al. CELL CYCLE
- Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer
- (2011) Céline Montavon et al. GYNECOLOGIC ONCOLOGY
- PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
- (2011) Stuart L. Rulten et al. MOLECULAR CELL
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
- (2011) C. Boehler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance
- (2010) Weixin Wang et al. CANCER BIOLOGY & THERAPY
- 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
- (2010) N. Issaeva et al. CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- MicroRNA: Biogenesis, Function and Role in Cancer
- (2010) Leigh-Ann MacFarlane et al. CURRENT GENOMICS
- Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
- (2010) Nancie Petrucelli et al. GENETICS IN MEDICINE
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- (2010) Raga Krishnakumar et al. MOLECULAR CELL
- Purified human BRCA2 stimulates RAD51-mediated recombination
- (2010) Ryan B. Jensen et al. NATURE
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer
- (2009) Michael J. Hall et al. CANCER
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Cells deficient in PARP-1 show an accelerated accumulation of DNA single strand breaks, but not AP sites, over the PARP-1-proficient cells exposed to MMS
- (2009) Brian F. Pachkowski et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
- (2009) Maximina H. Yun et al. NATURE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sgs1 Helicase and Two Nucleases Dna2 and Exo1 Resect DNA Double-Strand Break Ends
- (2008) Zhu Zhu et al. CELL
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
- (2008) Kazuto Sugimura et al. JOURNAL OF CELL BIOLOGY
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility
- (2008) C. Godon et al. NUCLEIC ACIDS RESEARCH
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation